Accordingly, the focus of this mini-review will be to characterize the alterations in intermediary metabolism that accompany TAFAZZIN deficiency, and to discuss the potential of targeting these pathways as a therapeutic approach to mitigate the development and progression of BTHS-related cardiomyopathy (Figure 1). Here, TAFAZZIN is linked to cardiomyopathy.